Oct. 25 at 2:48 PM
$MDNAF Came across an article, last updated in June 2025, focusing on IL-2 superkines. See the table listing the many companies involved in IL-2 development, including Medicenna. Xilio has since discontinued XTX202. Unless I missed it, not one of the publicly traded companies from the list has had anywhere near MDNAF’s meteoric rise since Wednesday’s Takeda/Innovent deal announcement.
https://www.labiotech.eu/more-news/il-2-smart-cytokines/